Lee M Krug MD

Oncology•New York, NY

Associate Professor, Medicine, Weill Cornell Medical College

Join to View Full Profile

1275 York AveNew York, NY 10065
Phone+1 212-639-2000

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
Johns Hopkins UniversityResidency, Internal Medicine, 1994 - 1997
Washington University in St. Louis School of MedicineClass of 1994

Certifications & Licensure

NY State Medical License 1997 - 2027

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2010-2014

Clinical Trials

10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Start of enrollment: 1999 Jul 01
Completed
Phase 2
Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy Start of enrollment: 1998 Aug 01
Completed
Phase 2
Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer Start of enrollment: 1999 Jul 01
Completed
Phase 1
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma Start of enrollment: 2001 Jul 01
Terminated
Phase 2
Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2002 Jul 01
Completed
Phase 1
A Multicenter Phase II Trial of Neo-Adjuvant Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma Start of enrollment: 2003 Jul 01
Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC) Start of enrollment: 2004 Jul 26
Completed
Phase 1
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma Start of enrollment: 2006 Oct 01
Completed
Phase 1
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2007 Mar 15
Completed
Phase 1, Phase 2
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors Start of enrollment: 2007 Aug 01
Completed
Phase 1, Phase 2
Continuation Clinical Trial of Oral L-0010790038 in Advanced Cancer Start of enrollment: 2005 Aug 01
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma Start of enrollment: 2008 Oct 11
Active, not recruiting
Phase 2
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity Start of enrollment: 2009 Dec 01
Completed
Phase 2
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy Start of enrollment: 2010 Dec 21
COMPLETED
PHASE2
Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid Start of enrollment: 2011 May 01
Completed
Phase 1
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma Start of enrollment: 2011 May 01
Completed
Not Applicable
Do Your Genes Put You at a Higher Risk of Developing Mesothelioma Start of enrollment: 2011 Jun 01
Completed
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent Start of enrollment: 2016 Mar 15
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study.
Jimmy Zhijian He, Vincent Duval, Petra Jauslin, Antonio Gonçalves, Aburough Abegesah
Clinical Pharmacology and Therapeutics. 2023-12-01
3 citations
Population pharmacokinetic modelling of tremelimumab in patients with advanced solid tumours and the impact of disease status on time-varying clearance.
Michael Hwang, Yen Lin Chia, Yanan Zheng, Cecil Chi-Keung Chen, Jimmy He
British Journal of Clinical Pharmacology. 2023-05-01
56 citations
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Jarushka Naidoo, Catherine Murphy, Michael B Atkins, Julie R Brahmer, Stephane Champiat
Journal for Immunotherapy of Cancer. 2023-03-01